Navigation Links
Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays

Agreement Generates New Diagnostic Opportunities at 120 Hospital-Affiliated

Labs Nationwide

ALISO VIEJO, Calif., May 6 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has signed a one-year agreement with Joint Venture Hospital Laboratories (JVHL) to provide a wide-range of cancer testing to its 120 hospital-affiliated labs. JVHL is located in Allen Park, Michigan and the agreement is renewable after the first year.

"This partnership provides more testing options for the pathologists and hospitals in the JVHL network," said Paul Valenstein, M.D., President of JVHL. "We are encouraged by this new relationship with Clarient and are pleased to provide our doctors with the benefit of Clarient's cancer assays."

"Working with JVHL and its network hospitals enables Clarient to compete directly with other large laboratories in the managed care markets and gives Clarient access to many new physicians and their patients," said Ron Andrews, CEO of Clarient. "Our agreement compliments our goal to work closely with community pathologists, who through this association will be able to enjoy the benefits of collaborating with a first-class cancer laboratory. We look forward to building upon this impactful association with JVHL for years to come."

About JVHL

The 120 hospital-affiliated laboratories comprising the JVHL Network are committed to providing managed care plan members and participating physicians with the highest quality, convenient and efficient laboratory services. Lab testing is one of the most vital diagnostic tools for all segments of health care. Through JVHL, and its success in contracting with managed care plans, hospital affiliated laboratories can provide their testing and consultative services to hospital and community based physicians and their patients. JVHL holds agreements with 19 managed care companies on behalf of its 120 network affiliated hospitals to provide outpatient and outreach laboratory services to more than 2 million managed care members.

About Clarient

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company.

About Safeguard

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS), Technology-Enabled Services and Internet-based Businesses, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings.

The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: Clarient's ability to continue to develop and expand its diagnostic services business, Clarient's ability to expand and maintain a successful sales and marketing organization, Clarient's ability to maintain compliance with financial and other covenants under its credit facilities, the continuation of favorable third party payer reimbursement for laboratory tests, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, Clarient's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.


Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Clarient Reports First Quarter 2008
2. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
3. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
4. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
5. Clarient Generates 52% Revenue Increase in Third Quarter 2007
6. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
7. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
8. Clarient to Present at the UBS 2007 Global Life Sciences Conference
9. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
10. Macerich Connects Women and Giving in Partnership with Step Up Womens Network
11. UPDATE: Retirement Living TV Partners With Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: